Groundbreaking research reveals how a cancer drug could restore brain function in early Alzheimer's patients by targeting glucose metabolism. Here's what you need to know.
The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...
SALT LAKE CITY — After years of stagnation in the search for a cure for Alzheimer's — or at least breakthroughs — 2024 brought several exciting findings and confirmed others regarding the ...